Investor Centre Analysts Reports

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle.

The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea and has two lead clinical assets. IMM-124E is in Phase 2 clinical trials for NASH, ASH and pediatric NAFLD and IMM-529 is in clinical development for clostridium difficile infections. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

Payment Options

Contact Information

Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Phone: +613 8892 4802
Fax: +613 9899 8533

Categories

Information

Analysts Reports

Immuron takes aim at the rapid growth of autoimmune diseases

Immuron surges 28pc after study shows tablets fight Bali Belly in US soldiers (Jan 2018)

Van Leeuwenhoeck Institute Updated Report (Nov 2017)

Emerging Biologics in Fatty-Liver and Infectious Disease Management (Sep 2017)

BioShares Report - Edition 687 (Mar 2017)

Van Leeuwenhoeck Institute Report - Substantial Re-rating in NASH (Feb 2017)

Van Leeuwenhoeck Institute Independent Research Note (Jan 2017)

SeeThru Equity Analyst Report (Feb 2016)

Red Chip C-Difficile Analyst Report (Jan 2016)

Red Chip Analyst Report (Aug 2015)

Partners

Secure Shopping

Get Connected

About Us

Information

Payment Options

Contact Information